- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Adam Simmons Explains the Importance of Finding New Treatment Options for Schizophrenia
Adam Simmons, director of clinical program management, Alkermes, explained why researchers are seeking new treatments for schizophrenia, such as the investigational treatment ALKS 3831, despite the efficacy of a commonly used antipsychotic, olanzapine. Simmons was interviewed at the 175th Annual Meeting of the American Psychiatric Association in San Francisco, California.
Adam Simmons, director of clinical program management, Alkermes, explained why researchers are seeking new treatments for schizophrenia, such as the investigational treatment ALKS 3831, despite the efficacy of a commonly used antipsychotic, olanzapine.
Transcript
Can you discuss the importance of finding new treatment options for people with schizophrenia?
Although there’s been a number of treatments and new therapies that have been developed since olanzapine’s come to the market, we still know that olanzapine is still one of the most effective antipsychotics, that it’s one of the most commonly used. And that being despite the fact that olanzapine has this propensity for causing large, clinically significant amounts of weight gain.
So the objective here, and what it is that we’ve tried to do with our development program, is demonstrate that we still have that same efficacy of olanzapine that has been established and is very well supported in the literature, but reducing some of that weight gain. And the benefits there, of course, are that we know that weight gain is associated with, as you mentioned, cardiovascular disease, diabetes, as well as the social reasons and stigma that goes along with increased amounts of weight gain.
So for people that need the efficacy of olanzapine but without that additional weight gain and all the disadvantages that go along with that, that’s where we think that 3831 offers a benefit for patients.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
